Limonin compound Munronin V as well as preparation method, derivative, pharmaceutical composition and application thereof
The invention provides a limonin compound MunroninV as well as a preparation method, a derivative, a pharmaceutical composition and application thereof, and relates to the technical field of medicines. The limonin compound MunroninV with the structure as shown in the formula I, the derivative (pharmaceutically acceptable salt, ester and stereoisomer) of the limonin compound and the pharmaceutical composition all have the effects of removing pathological microtubule-related protein Tau by activating autophagy, improving the bioavailability of the limonin compound and improving the bioavailability of the limonin compound. The limonin compound MunroninV is shown to have the activity of preventing and treating the Alzheimer's disease, and has good value and application prospect in preparation of the medicine for resisting the Alzheimer's disease. According to the preparation method disclosed by the invention, the rehmannia glutinosa libosch is used as a preparation raw material of the limonin compound Munronin V, the operation is simple, the preparation condition is mild, the raw material source is wide, the production cost is low, and the preparation method is suitable for industrial production..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 23. Juni Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
YAN YING [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-06-23, Last update posted on www.tib.eu: 2023-11-21, Last updated: 2023-11-24 |
|---|
| Patentnummer: |
CN116284038 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018113516 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018113516 | ||
| 003 | DE-627 | ||
| 005 | 20231124094829.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231006s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018113516 | ||
| 035 | |a (EPA)CN116284038 | ||
| 035 | |a (EPA)86822775 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a YAN YING |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Limonin compound Munronin V as well as preparation method, derivative, pharmaceutical composition and application thereof |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-06-23, Last update posted on www.tib.eu: 2023-11-21, Last updated: 2023-11-24 | ||
| 520 | |a The invention provides a limonin compound MunroninV as well as a preparation method, a derivative, a pharmaceutical composition and application thereof, and relates to the technical field of medicines. The limonin compound MunroninV with the structure as shown in the formula I, the derivative (pharmaceutically acceptable salt, ester and stereoisomer) of the limonin compound and the pharmaceutical composition all have the effects of removing pathological microtubule-related protein Tau by activating autophagy, improving the bioavailability of the limonin compound and improving the bioavailability of the limonin compound. The limonin compound MunroninV is shown to have the activity of preventing and treating the Alzheimer's disease, and has good value and application prospect in preparation of the medicine for resisting the Alzheimer's disease. According to the preparation method disclosed by the invention, the rehmannia glutinosa libosch is used as a preparation raw material of the limonin compound Munronin V, the operation is simple, the preparation condition is mild, the raw material source is wide, the production cost is low, and the preparation method is suitable for industrial production. | ||
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a NA YOUNG-CHAN |4 aut | |
| 700 | 0 | |a RAN XIAOQIAN |4 aut | |
| 700 | 0 | |a YAO YONGGANG |4 aut | |
| 700 | 0 | |a HAO XIAOJIANG |4 aut | |
| 700 | 0 | |a TANG LEI |4 aut | |
| 700 | 0 | |a WANG DAN |4 aut | |
| 700 | 0 | |a PENG MINGYOU |4 aut | |
| 700 | 0 | |a ZHANG XIONG |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 23. Juni |
| 773 | 1 | 8 | |g year:2023 |g day:23 |g month:06 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/86822775/publication/CN116284038A1?q=CN116284038 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 23 |c 06 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 23 |c 06 | ||